ProCE Banner Activity

Considerations for Therapy Selection in Patients with R/R MM After BCMA-Targeted Treatment: Future Directions

Slideset Download
Download these slides from a live symposium for an expert review of the potential treatment options for patients with R/R MM after previous BCMA-targeted therapy.

Released: December 09, 2022

Expiration: December 08, 2023

No longer available for credit.

Share

Faculty

Yi Lin

Yi Lin

Professor of Medicine, Division of Hematology
Division of Experimental Pathology
Chair, Cell Therapy Cross-Disciplinary Group
Mayo Clinic Comprehensive Cancer Center
Associate Medical Director, Mayo Clinic Center for Regenerative Biotherapeutics
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Janssen administered by Scientific Affairs

Karyopharm Therapeutics Inc.

Pfizer, Inc.

Regeneron Pharmaceuticals, Inc.

Takeda Pharm USA

Partners

International Myeloma Foundation

ProCE Banner

Faculty Disclosure

Primary Author

Yi Lin,

Professor of Medicine, Division of Hematology
Division of Experimental Pathology
Chair, Cell Therapy Cross-Disciplinary Group
Mayo Clinic Comprehensive Cancer Center
Associate Medical Director, Mayo Clinic Center for Regenerative Biotherapeutics
Mayo Clinic
Rochester, Minnesota